Thomas Schinecker became CEO of Roche in March.
Keystone
Swiss pharmaceuticals group Roche is not ruling out further acquisitions.
This content was published on
2 minutes
Keystone-SDA/ds
But a major takeover must make “scientific and financial sense”, says the company’s CEO, Thomas Schinecker.
Interviewed on Sunday in the NZZ am Sonntag, he says he does not want to speculate on figures.
Schinecker has been at the helm of the Basel-based group since March. The worst approach, he says, would be “for the new guy to come in and say this is how we do it”. His task is to create the framework conditions so that changes can be implemented as quickly as possible, he adds.
Highly innovative projects
He says he has noticed a potential for improvement in the quality of research projects. When it comes to highly innovative molecules, the pharmaceutical group is at the forefront, he explains. But “it’s true that we also have a number of projects where we’re only in the middle of the pack”.
Future investments will therefore be geared more towards highly innovative projects, he continues, stressing that the most promising projects must also progress more rapidly.
Roche’s three research centers in Basel, California and Japan will remain independent, according to the CEO, who does not envisage any reorganisation. “Such a measure would lead to insecurity among employees and paralyze the organization for years to come,” he says.
More
More
The end of affordable medicine
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Culture
Documentary portrays Swiss teenagers forced to return to parents’ homeland
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
AI can reduce the number of animals needed for research
This content was published on
Swiss researchers have developed a new, AI-supported method that analyses the behaviour of mice in the laboratory more efficiently.
Geneva Conventions conference on Middle East scheduled for March 2025
This content was published on
The conference on the Middle East of the 196 States party to the Geneva Conventions, organised by Switzerland, will take place in Geneva in March.
Swiss university graduates are popular hires worldwide
This content was published on
Graduates of Swiss universities are popular with international employers, according to the Global Employability University Rankings.
French cross-border workers in Switzerland fear ‘discriminatory’ unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Roche to focus on R&D, no job cuts in 2023, says new CEO
This content was published on
The Swiss pharma giant intends to invest more in research and development this year, according to Roche’s new CEO Thomas Schinecker.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.